Gemcitabine and Cisplatin (DD GC)

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Assiut University

Conditions

Bladder CancerUrinary Bladder Cancer

Phase 2

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

CompletedNCT01589094

Memorial Sloan Kettering Cancer CenterBladder Cancer

Start: 2012-04-30End: 2018-08-31Updated: 2019-10-02

Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer

Not yet recruitingNCT07184021

Assiut UniversityUrinary Bladder Cancer

Start: 2025-09-30End: 2027-09-30Target: 30Updated: 2025-09-19

Related Papers

Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC).

Journal of Clinical Oncology2016-05-2013 citations

Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology2016-01-107 citations